- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02619292
Mindful Movement for Breast Cancer Survivors
July 12, 2017 updated by: Saint John's Cancer Institute
The purpose of this study is to determine if participating in a Mindful Movement Program (MMP) (learning how to be mindful in one's movement), positively affects the body's immune functions improves mindfulness and reduces worries about cancer returning.
All participants will be in this study about three months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Breast cancer survivors (BCS) may experience psychological and physical effects long after treatment is over.
Some research shows that practicing mindfulness, and movement types of activities such as qi gong or yoga may lead to improvements in emotional and physical well-being, including improved immune function.
Immune function can be negatively affected by stress and worry, and this has an unknown effect on the risk of cancer recurrence.
Psychological and physical interventions that help enhance an individual's wellbeing and reduce stress and worry may have a positive influence on immune function and in turn, reduce the risk of cancer recurrence.
While there is limited research in this area, and none with dance therapy, little attention has been given to older BCS.
However, understanding of immune function suggests that older women may be the best group to target for such interventions.
Previous research with BCS age 50 or older who participated in a 12-week program combining mindfulness practice with dance/movement therapy (Mindful Movement Program) demonstrated positive effects: participants were more mindful in their day-to-day living and had less worry about the cancer coming back.
Participants also reported through focus groups that the Mindful Movement Program (MMP) had improved their overall well-being.
No laboratory tests of the body's immune response to MMP were included.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90404
- Margie Petersen Breast Center at Providence Saint John's Health Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- diagnosed at age 50 or older with stage 0-III disease
- 6 months or more since completion of primary breast cancer treatment
- have a medical release from their physician
- English-speaking
- not pregnant
- no weekly practice of yoga, qi gong, tai chi, dance/movement therapy, or mindfulness meditation practice
Exclusion Criteria:
- Males with breast cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindful Movement Program
Mindfulness is "moment-to-moment, present-centered, purposive non-judgmental awareness"; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals
|
Mindfulness is turning one's awareness to the present moment.
Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune markers
Time Frame: 18 weeks
|
Improvement in serum markers of immune cell phenotype at week 18
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mindful Movement Intervention Experience
Time Frame: 18 weeks
|
Improvement in mindfulness attitude as measured on Meditative Movement Inventory (MMI)
|
18 weeks
|
Mindful Movement Intervention Experience
Time Frame: 18 weeks
|
Improvement in mindfulness attitude as measured on Perceived Exertion Scale (PES)
|
18 weeks
|
Mindful Movement Intervention Experience - Mindfulness Intention
Time Frame: 18 weeks
|
Improvement in mindfulness attitude as measured on Mindfulness Intention (modified from Segal, 1-item)
|
18 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fear of Recurrence
Time Frame: 18 weeks
|
Fear of recurrence as measured on Fear of Recurrence (FOR) scale
|
18 weeks
|
Mindfulness attention
Time Frame: 18 weeks
|
Improvement in mindfulness attitude as measured with the Mindful Attention Awareness Scale (MAAS)
|
18 weeks
|
Mindfulness attitude
Time Frame: 18 weeks
|
Improvement in mindfulness attitude as measured with the Experiences Questionnaire (EQ)
|
18 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rebecca Crane-Okada, PhD, RN, Saint John's Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
November 6, 2015
First Submitted That Met QC Criteria
November 30, 2015
First Posted (Estimate)
December 2, 2015
Study Record Updates
Last Update Posted (Actual)
July 14, 2017
Last Update Submitted That Met QC Criteria
July 12, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMP-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Mindful Movement Program
-
The Miriam HospitalRhode Island FoundationNot yet recruitingEndometriosis | Pelvic Pain
-
Hugo W. Moser Research Institute at Kennedy Krieger...National Center for Advancing Translational Sciences (NCATS)Enrolling by invitationMindful Movement Intervention (MMI)United States
-
Wake Forest University Health SciencesCompletedPain | Psychological Distress | Surgical Complications | Lung Function | Gynecologic Malignancy | Abdominal Surgery by LaparotomyUnited States
-
Drexel UniversityCompletedPhysical Activity | Cognitive Decline | Psychological WellbeingUnited States
-
University of MinnesotaNational Center for Complementary and Integrative Health (NCCIH); YMCACompletedWellbeing | Mindfulness | Physical InactivtyUnited States
-
Wayne State UniversityCompleted
-
University of MinnesotaNational Center for Complementary and Integrative Health (NCCIH); YMCACompletedPhysical InactivityUnited States
-
University of Texas Southwestern Medical CenterCompletedDepression | Pain | Anxiety StateUnited States
-
New York UniversityCompletedAttention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder | Disruptive BehaviorUnited States
-
Istanbul University - Cerrahpasa (IUC)Health Institutes of TurkeyNot yet recruitingBreast Feeding | Mindfulness | Psychological Well-BeingTurkey